Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Media, Education & EngagementEducational Platforms & ResourcesOnline Resources
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing
Media, Education & EngagementEducational Platforms & Resources
Media, Education & Engagement

Johns Hopkins University

United States
22 Trials5 Papers

The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.

Course Provider

0 active

Active Courses

0

Upcoming Cohorts

0

Evergreen

0

Price Range

Varies

Course Status

Showing 0of 2linked courses for Johns Hopkins University.
No courses match the selected filters.

Academic Research

5 papers

Published Papers

5

Trial Involvement

22

Distinct Focus Topics

0

Latest Publication

Mar 10, 2026

Quick Facts

Type
academic
HQ
United States
Website
Visit

Sponsored Trials

20
Not yet recruitingI

Shortened LSD Intervention for Major Depressive Disorder

Start Date
Compounds
LSD, Placebo
RecruitingI

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Start Date
Compounds
Psilocybin
RecruitingI

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) (PAM-VET)

Start Date
Compounds
MDMA, Psilocybin
RecruitingI

Psilocybin Brain Stimulation and Imaging Pilot Study (OPTE)

Start Date
Compounds
Psilocybin
WithdrawnII

Trifecta Research Study

Start Date
Compounds
Ibogaine, 5-MeO-DMT
RecruitingI

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Start Date
Compounds
Psilocybin
RecruitingI

Investigation of Psychedelic Effects in Psychoactive Substances

Start Date
Compounds
Placebo, Psilocybin, Ketamine, DMT, MDMA
RecruitingI

Psilocybin-assisted Treatment for Cannabis Use Disorder

Start Date
Compounds
Psilocybin
RecruitingI

Safety for Home Administration of Microdose Psilocybin Use

Start Date
Compounds
Psilocybin, Placebo
Active not recruitingI

A Study of Psilocybin for PTSD (PSI-3PO)

Start Date
Compounds
Psilocybin
RecruitingI

Psilocybin in Chronic Low Back Pain and Depression

Start Date
Compounds
Psilocybin, Placebo
RecruitingII

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Start Date
Compounds
Psilocybin
WithdrawnII

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-In)

Start Date
Compounds
Psilocybin
WithdrawnI

Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder

Start Date
Compounds
Psilocybin
RecruitingI

Effects of Psilocybin in Obsessive Compulsive Disorder

Start Date
Compounds
Psilocybin
RecruitingII

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Start Date
Compounds
Psilocybin, Placebo
CompletedI

Effects of Psilocybin in Post-Treatment Lyme Disease

Start Date
Compounds
Psilocybin
RecruitingI, II

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Start Date
Compounds
Psilocybin, Placebo
WithdrawnII

Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

Start Date
Compounds
Psilocybin, Placebo
Active not recruitingII

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

Start Date
Compounds
Psilocybin, Placebo

Collaborated Trials

2
RecruitingII

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)

Start Date
Compounds
Psilocybin
Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date
Compounds
Ketamine, Placebo

Research Papers

5
Open Accessindividual

Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial

This pilot randomised clinical trial (n=82) found that a single dose of psilocybin (30mg/70kg) combined with cognitive behavioural therapy produced significantly higher long-term smoking abstinence rates at 6 months compared to nicotine patches plus CBT (41% vs 10%), with no serious adverse events attributed to either treatment.

Published
Journal
JAMA Network Open
Authors
Johnson, M. W., Naudé, G. P., Hendricks, P. S., Garcia-Romeu, A.
Open Accessindividual

Pilot study of psilocybin in patients with post-treatment lyme disease

In an open‑label, single‑arm pilot study of 20 patients with post‑treatment Lyme disease, two psilocybin sessions with psychological support produced significant, sustained reductions in symptom burden (40% decrease in GSQ‑30 at six months) and improvements in both physical and mental quality of life. The intervention was feasible and well-tolerated with no serious related adverse events, supporting further controlled trials of psilocybin‑assisted therapy for PTLD.

Published
Journal
Scientific Reports
Authors
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., Aucott, J. N.
Open Accessmeta

Psychedelic medicine: mechanisms, evidence, and translation to practice

This review (2026) summarises the rapidly growing evidence for psychedelic-assisted therapies, finding the strongest support for psilocybin in treatment-resistant depression (TRD) and MDMA in post-traumatic stress disorder (PTSD). It also highlights that while these treatments are generally well tolerated in controlled settings, major challenges remain around unclear mechanisms, trial limitations, scalability, and translation into routine practice.

Published
Journal
BMJ
Authors
Jacobs, E., Zahid, Z., Hinkle, J., Nayak, S., Yaden, D. B.
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.
Open Accessindividual

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

In a randomised, parallel-group waitlist-controlled exploratory study (n=29) of psychedelic-naïve clergy, two supported psilocybin sessions were well tolerated and produced significant, sustained increases in religious practices, attitudes, perceived leadership effectiveness, and broader psychological wellbeing. These effects persisted up to 16 months and were frequently rated among participants' most spiritually meaningful experiences.

Published
Journal
Psychedelic Medicine
Authors
Griffiths, R. R., Jesse, R., Richards, W. A., Johnson, M. W., Sepeda, N. D., Bossis, A. P., Ross, S.